MA50201A - Comprimés de défériprone à libération retardée et procédés d'utilisation correspondants - Google Patents
Comprimés de défériprone à libération retardée et procédés d'utilisation correspondantsInfo
- Publication number
- MA50201A MA50201A MA050201A MA50201A MA50201A MA 50201 A MA50201 A MA 50201A MA 050201 A MA050201 A MA 050201A MA 50201 A MA50201 A MA 50201A MA 50201 A MA50201 A MA 50201A
- Authority
- MA
- Morocco
- Prior art keywords
- deferiprone
- delayed
- related methods
- release tablets
- tablets
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
- A61K9/204—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/04—Chelating agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Hospice & Palliative Care (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Inorganic Chemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762577055P | 2017-10-25 | 2017-10-25 | |
| US201762596043P | 2017-12-07 | 2017-12-07 | |
| EP18871663.3A EP3684344B1 (fr) | 2017-10-25 | 2018-10-25 | Comprimés de défériprone à libération retardée et procédés d'utilisation correspondants |
| PCT/IB2018/058350 WO2019082128A1 (fr) | 2017-10-25 | 2018-10-25 | Comprimés de défériprone à libération retardée et procédés d'utilisation correspondants |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA50201A true MA50201A (fr) | 2021-04-28 |
| MA50201B1 MA50201B1 (fr) | 2025-07-31 |
Family
ID=66170815
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA50201A MA50201B1 (fr) | 2017-10-25 | 2018-10-25 | Comprimés de défériprone à libération retardée et procédés d'utilisation correspondants |
Country Status (30)
| Country | Link |
|---|---|
| US (8) | US10940116B2 (fr) |
| EP (2) | EP4635573A3 (fr) |
| JP (1) | JP7246384B2 (fr) |
| KR (1) | KR102624627B1 (fr) |
| CN (2) | CN114533689A (fr) |
| AU (1) | AU2018357350B2 (fr) |
| BR (1) | BR112020008128A2 (fr) |
| CA (2) | CA3172668A1 (fr) |
| DK (1) | DK3684344T3 (fr) |
| ES (1) | ES3036967T3 (fr) |
| FI (1) | FI3684344T3 (fr) |
| HR (1) | HRP20251151T1 (fr) |
| HU (1) | HUE073016T2 (fr) |
| IL (2) | IL273955B2 (fr) |
| LT (1) | LT3684344T (fr) |
| MA (1) | MA50201B1 (fr) |
| MD (1) | MD3684344T2 (fr) |
| MX (1) | MX2020004107A (fr) |
| MY (1) | MY204588A (fr) |
| NZ (2) | NZ787785A (fr) |
| PH (1) | PH12020550815A1 (fr) |
| PL (1) | PL3684344T3 (fr) |
| PT (1) | PT3684344T (fr) |
| RS (1) | RS67157B1 (fr) |
| SA (1) | SA520411808B1 (fr) |
| SG (1) | SG11202003153TA (fr) |
| SI (1) | SI3684344T1 (fr) |
| SM (1) | SMT202500358T1 (fr) |
| UA (1) | UA126977C2 (fr) |
| WO (1) | WO2019082128A1 (fr) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3684344T3 (da) | 2017-10-25 | 2025-08-04 | Chiesi Farm Spa | Deferipron-tabletter med forsinket frigivelse og fremgangsmåder til anvendelse deraf |
| AU2023254403A1 (en) | 2022-04-11 | 2024-11-21 | Chiesi Farmaceutici S.P.A. | Modified release pharmaceutical formulations comprising deferiprone |
| US12016851B2 (en) | 2022-04-11 | 2024-06-25 | Chiesi Farmaceutici S.P.A. | Modified release pharmaceutical formulations comprising deferiprone |
| US12016850B2 (en) | 2022-04-11 | 2024-06-25 | Chiesi Farmaceutici S.P.A. | Modified release pharmaceutical formulations comprising deferiprone |
| EP4507679A1 (fr) | 2022-04-11 | 2025-02-19 | Chiesi Farmaceutici S.p.A. | Formulations pharmaceutiques à libération modifiée comprenant de la défériprone |
| EP4601625A1 (fr) * | 2022-10-14 | 2025-08-20 | Chiesi Farmaceutici S.p.A. | Formulations pharmaceutiques à libération modifiée comprenant de la défériprone |
| KR20260018073A (ko) | 2023-05-25 | 2026-02-06 | 키에시 파르마슈티시 엣스. 피. 에이. | 맥동성 방출을 위한 약제학적 제형 |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI98343C (fi) * | 1995-03-21 | 1997-06-10 | Orion Yhtymae Oy | Peroraalinen formulaatio |
| US5747532A (en) | 1995-11-21 | 1998-05-05 | Medinox, Inc. | Combinational therapeutic methods employing nitric oxide scavengers and compositions useful therefor |
| GB9625638D0 (en) | 1996-12-10 | 1997-01-29 | Cenes Ltd | Therapeutic antioxidants for alzheimer's diease |
| EP1246606A2 (fr) | 1999-12-30 | 2002-10-09 | Judith K. Gwathmey | Systeme de distribution de chelateur de fer |
| CA2313270C (fr) * | 2000-06-30 | 2011-09-13 | Apotex Inc. | Utilisation de deferiprone pour le traitement et la prevention de maladies cardiaques induites par le fer |
| US20040101521A1 (en) | 2002-07-12 | 2004-05-27 | The Buck Institute For Research On Aging | Iron sequestration or elimination to reduce neurodegeneration or Parkinsons disease progression |
| US7985422B2 (en) | 2002-08-05 | 2011-07-26 | Torrent Pharmaceuticals Limited | Dosage form |
| US8268352B2 (en) | 2002-08-05 | 2012-09-18 | Torrent Pharmaceuticals Limited | Modified release composition for highly soluble drugs |
| AU2003282337B2 (en) | 2002-11-07 | 2009-07-16 | Technion Research And Development Foundation Ltd. | Neuroprotective iron chelators and pharmaceutical compositions comprising them |
| CA2576190A1 (fr) | 2004-08-06 | 2006-02-16 | Shiva Biomedical, Llc | Procedes de traitement d'humains recevant une injection d'un agent de contraste |
| GB0502475D0 (en) * | 2005-02-07 | 2005-03-16 | Sb Pharmco Inc | Novel compositions |
| MY151412A (en) | 2006-02-22 | 2014-05-30 | Munnich Arnold | The use of deferiprone and methods to treat and/or prevent friedreich ataxia resulting from intracellular mishandling of iron |
| MX2009002235A (es) | 2006-08-30 | 2009-03-13 | Jagotec Ag | Formulaciones de dosis oral, solidas, de liberacion controlada que comprenden nisoldipina. |
| US9744137B2 (en) | 2006-08-31 | 2017-08-29 | Supernus Pharmaceuticals, Inc. | Topiramate compositions and methods of enhancing its bioavailability |
| US20080138440A1 (en) | 2006-11-29 | 2008-06-12 | Cormedix Inc. | Methods of diagnosing and alleviating gadolinium toxicity |
| CN101352438A (zh) | 2007-07-25 | 2009-01-28 | 复旦大学 | 去铁酮及其制剂在制备防治蒽环类药物心脏毒性药物中的用途 |
| PL2268282T3 (pl) | 2008-04-25 | 2015-04-30 | Apotex Tech Inc | Płynny preparat deferypronu o przyjemnym smaku |
| US20110189260A1 (en) | 2008-05-30 | 2011-08-04 | University Of Cincinnati | Use of zinc chelators to inhibit biofilm formation |
| WO2010005851A1 (fr) | 2008-07-08 | 2010-01-14 | Xenon Pharmaceuticals Inc. | Polythérapie destinée au traitement de troubles du fer |
| US20100255082A1 (en) * | 2008-07-31 | 2010-10-07 | Ishwar Chauhan | Functionally Coated Breakable Tablets |
| EP2206506A1 (fr) | 2008-12-18 | 2010-07-14 | Bracco Imaging S.p.A | Formulations probiotiques |
| NZ594728A (en) | 2009-01-26 | 2013-03-28 | Univ Pennsylvania | Use of deferiprone for treatment and prevention of iron-related eye disorders |
| US8603814B2 (en) | 2009-07-20 | 2013-12-10 | Rutgers The State University Of New Jersey | Method of inhibiting nonsense-mediated mRNA decay |
| US20120172292A1 (en) | 2009-09-10 | 2012-07-05 | New York University | Method for protection of antimicrobial and anticancer drugs from inactivation by nitric oxide |
| US8563035B2 (en) * | 2010-05-05 | 2013-10-22 | Sanovel Ilac Sanayi Ve Ticaret Anomin Sirketi | Oral tablet compositions of dexlansoprazole |
| WO2012094598A2 (fr) * | 2011-01-07 | 2012-07-12 | Merrion Research Iii Limited | Compositions pharmaceutiques de fer pour administration orale |
| DE102011112898A1 (de) | 2011-09-08 | 2013-03-14 | Charité - Universitätsmedizin Berlin | Nanopartikuläres Phosphatadsorbens basierend auf Maghämit oder Maghämit/Magnetit, dessen Herstellung und Verwendungen |
| BR112014012054A2 (pt) | 2011-11-18 | 2017-05-30 | Apotex Tech Inc | métodos de tratamento com deferiprona |
| WO2013139931A1 (fr) | 2012-03-21 | 2013-09-26 | Icm (Institut Du Cerveau Et De La Moelle Épinière) | Composition destinée à être utilisée dans le traitement de maladies neurodégénératives ayant des syndromes parkinsoniens |
| US20150246027A1 (en) | 2012-11-12 | 2015-09-03 | Cipla Limited | Fixed dose pharmaceutical composition comprising deferasirox and deferiprone |
| HK1215191A1 (zh) | 2013-05-10 | 2016-08-19 | Cipla Limited | 低剂量医药组合物 |
| MX377119B (es) * | 2013-06-06 | 2025-03-07 | Amip Llc | Un sistema de dosis no alimenticia suministrable oralmente que comprende hierro y un agente. |
| ITMI20132066A1 (it) * | 2013-12-11 | 2015-06-12 | Farmatron Ltd | Sistemi terapeutici a rilascio modificato per la somministrazione orale di mentolo nel trattamento delle malattie intestinali |
| KR102480882B1 (ko) | 2016-08-05 | 2022-12-26 | 아브페로 파마슈티칼스, 인크. | 금속-매개 상태를 치료하기 위한 투여 요법 |
| US20180362228A1 (en) | 2017-02-16 | 2018-12-20 | Jeffrey D. Jacobson | Container closure with integrated utensil |
| DK3684344T3 (da) | 2017-10-25 | 2025-08-04 | Chiesi Farm Spa | Deferipron-tabletter med forsinket frigivelse og fremgangsmåder til anvendelse deraf |
-
2018
- 2018-10-25 DK DK18871663.3T patent/DK3684344T3/da active
- 2018-10-25 AU AU2018357350A patent/AU2018357350B2/en active Active
- 2018-10-25 LT LTEPPCT/IB2018/058350T patent/LT3684344T/lt unknown
- 2018-10-25 MD MDE20200792T patent/MD3684344T2/ro unknown
- 2018-10-25 RS RS20250792A patent/RS67157B1/sr unknown
- 2018-10-25 CN CN202210164525.3A patent/CN114533689A/zh active Pending
- 2018-10-25 HR HRP20251151TT patent/HRP20251151T1/hr unknown
- 2018-10-25 IL IL273955A patent/IL273955B2/en unknown
- 2018-10-25 CA CA3172668A patent/CA3172668A1/fr not_active Withdrawn
- 2018-10-25 SG SG11202003153TA patent/SG11202003153TA/en unknown
- 2018-10-25 JP JP2020523267A patent/JP7246384B2/ja active Active
- 2018-10-25 EP EP25186255.3A patent/EP4635573A3/fr active Pending
- 2018-10-25 US US16/171,170 patent/US10940116B2/en active Active
- 2018-10-25 PL PL18871663.3T patent/PL3684344T3/pl unknown
- 2018-10-25 SM SM20250358T patent/SMT202500358T1/it unknown
- 2018-10-25 BR BR112020008128-0A patent/BR112020008128A2/pt unknown
- 2018-10-25 ES ES18871663T patent/ES3036967T3/es active Active
- 2018-10-25 UA UAA202003078A patent/UA126977C2/uk unknown
- 2018-10-25 KR KR1020207014502A patent/KR102624627B1/ko active Active
- 2018-10-25 SI SI201831250T patent/SI3684344T1/sl unknown
- 2018-10-25 IL IL321388A patent/IL321388A/en unknown
- 2018-10-25 CA CA3077514A patent/CA3077514C/fr not_active Expired - Fee Related
- 2018-10-25 PT PT188716633T patent/PT3684344T/pt unknown
- 2018-10-25 MX MX2020004107A patent/MX2020004107A/es unknown
- 2018-10-25 FI FIEP18871663.3T patent/FI3684344T3/fi active
- 2018-10-25 NZ NZ787785A patent/NZ787785A/en unknown
- 2018-10-25 HU HUE18871663A patent/HUE073016T2/hu unknown
- 2018-10-25 NZ NZ763555A patent/NZ763555A/en unknown
- 2018-10-25 US US16/759,254 patent/US20200253945A1/en not_active Abandoned
- 2018-10-25 MA MA50201A patent/MA50201B1/fr unknown
- 2018-10-25 MY MYPI2020002003A patent/MY204588A/en unknown
- 2018-10-25 WO PCT/IB2018/058350 patent/WO2019082128A1/fr not_active Ceased
- 2018-10-25 CN CN201880069331.7A patent/CN111918646B/zh active Active
- 2018-10-25 US US16/171,173 patent/US10780055B2/en active Active
- 2018-10-25 EP EP18871663.3A patent/EP3684344B1/fr active Active
-
2019
- 2019-12-13 US US16/714,520 patent/US11458103B2/en active Active
-
2020
- 2020-04-03 US US16/839,928 patent/US11357731B2/en active Active
- 2020-04-20 PH PH12020550815A patent/PH12020550815A1/en unknown
- 2020-04-21 SA SA520411808A patent/SA520411808B1/ar unknown
- 2020-05-12 US US15/930,373 patent/US10940115B2/en active Active
-
2021
- 2021-05-21 US US17/327,135 patent/US11723874B2/en active Active
-
2022
- 2022-05-12 US US17/742,960 patent/US11607389B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3695037A4 (fr) | Machine à tresser et ses procédés d'utilisation | |
| EP3634430A4 (fr) | Agents multibiotiques et procédés d'utilisation de ceux-ci | |
| EP3526379A4 (fr) | Machine à tresser et ses procédés d'utilisation | |
| EP3303634A4 (fr) | Variants de cas9 et procédés d'utilisation associés | |
| EP3652325A4 (fr) | Polynucléotides encapsulés et procédés d'utilisation | |
| EP3684423A4 (fr) | Virus adéno-associé à variant de capsides et leurs procédés d'utilisation | |
| EP3436048A4 (fr) | Néoantigènes et leurs procédés d'utilisation | |
| EP3487379A4 (fr) | Dispositifs médicaux et procédés d'utilisation | |
| EP3364946A4 (fr) | Systèmes à demeure gastriques pour libération prolongée d'agents thérapeutiques et leurs procédés d'utilisation | |
| MA42043A (fr) | Anticorps anti-ox40 et procédés d'utilisation de ceux-ci | |
| MA43018A (fr) | Anticorps anti-pd1 et procédés d'utilisation | |
| EP3394065A4 (fr) | Tétrahydropyranyl-amino-pyrrolopyrimidinone et procédés d'utilisation associés | |
| EP3377612A4 (fr) | Expression fonctionnelle de monooxygénases et procédés d'utilisation | |
| EP3510040A4 (fr) | Inhibiteurs d'éctonucléotidase et leurs procédés d'utilisation | |
| EP3635000A4 (fr) | Manabodies et procédés d'utilisation | |
| EP3303435A4 (fr) | Hydrofluoroléfines et procédés d'utilisation associés | |
| EP3515879A4 (fr) | Équipement de durcissement avancé et procédés d'utilisation de celui-ci | |
| EP3380181A4 (fr) | Cathéter à gaine orientable et procédés d'utilisation associés | |
| EP3271352A4 (fr) | Carbamates de pipérazine et procédés de préparation et d'utilisation de ceux-ci | |
| EP3710430A4 (fr) | Inhibiteurs d'acss2 et leurs procédés d'utilisation | |
| EP3706743A4 (fr) | Canaux ioniques modifiés sensibles à un ligand et méthodes d'utilisation | |
| EP3525855A4 (fr) | Inhalateur et procédés d'utilisation associés | |
| EP3349851A4 (fr) | Polypeptides photosensibles et leurs procédés d'utilisation | |
| EP3307172A4 (fr) | Cathéters d'imagerie intravasculaire et procédés d'utilisation correspondants | |
| EP3394098A4 (fr) | Anticorps anti-myostatine et procédés d'utilisation |